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Abstract
Background: Several alphaherpesviruses, including herpes simplex virus 1 (HSV-1) and pseudorabies virus (PRV), establish
lifelong latency in neurons of the trigeminal ganglion (TG). Although it is thought that efficient establishment of
alphaherpesvirus latency is based on a subtle interplay between virus, neurons and the immune system, it is not clear which
immune components are of major importance for the establishment of latency.
Methodology/Principal Findings: Here, using an in vitro model that enables a natural route of infection, we show that
interferon alpha (IFNalpha) has the previously uncharacterized capacity to induce a quiescent HSV-1 and PRV infection in
porcine TG neurons that shows strong similarity to in vivo latency. IFNalpha induced a stably suppressed HSV-1 and PRV
infection in TG neurons in vitro. Subsequent treatment of neurons containing stably suppressed virus with forskolin resulted
in reactivation of both viruses. HSV and PRV latency in vivo is often accompanied by the expression of latency associated
transcripts (LATs). Infection of TG neurons with an HSV-1 mutant expressing LacZ under control of the LAT promoter
showed activation of the LAT promoter and RT-PCR analysis confirmed that both HSV-1 and PRV express LATs during
latency in vitro.
Conclusions/Significance: These data represent a unique in vitro model of alphaherpesvirus latency and indicate that
IFNalpha may be a driving force in promoting efficient latency establishment.
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Introduction
Alphaherpesviruses are a subfamily of the herpesviruses
containing closely related human and animal pathogens, including
human HSV-1 (cold sores, corneal blindness, and encephalitis) and
important animal viruses such as the porcine pseudorabies virus
(PRV) and bovine herpesvirus 1 (BoHV-1; respiratory symptoms,
abortions, and/or neurological symptoms).
Cycles of latency and reactivation arguably constitute the most
important and fascinating hallmarks of alphaherpesvirus infec-
tions. Alphaherpesviruses generally establish latency in sensory
neurons, and neurons of the trigeminal ganglion (TG) are the
predominant site of latency for several important alphaherpes-
viruses, such as HSV-1, PRV, and BoHV-1 [1–3]. Although there
is direct and indirect evidence to support the general concept that
alphaherpesvirus latency and reactivation is based on a subtle
interplay between virus, neurons and the immune system, many
questions remain about the immune components that are involved
in the establishment of latency [4].
It is becoming increasingly clear that the innate immune system
has an important role in controlling alphaherpesvirus infections.
Type I interferons (IFNalpha and -beta) are among the first
immune effectors produced upon alphaherpesvirus infection [5,6]
and it has been shown that they are important in limiting viral
replication and spread in vitro, but also in vivo at the periphery
during initial infection and during reactivation [7–9]. Further-
more, type I interferons have been shown to be present at the
periphery [7] and within the ganglion [10] around the time point
that latency is established.
In the current study, using an in vitro two-chamber model that
enables a natural route of alphaherpesvirus infection of porcine
TG neurons [11,12], we report that treatment of TG neurons with
IFNalpha is sufficient to induce a quiescent HSV-1 and PRV
infection in vitro that shows strong similarities to in vivo latency,
thereby providing a novel and unique in vitro model to study
HSV/PRV latency and reactivation and suggesting that IFNalpha
may represent a key immune component involved in efficient
establishment of alphaherpesvirus latency in sensory neurons.
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Materials and Methods
Ethics statement
Trigeminal ganglia were derived from animals that were
euthanized at the Faculty of Veterinary Medicine, Ghent
University, Belgium, according to FELASA guidelines (Federation
of European Laboratory Animal Science Associations).
Cells and viruses
Wild type PRV strain Becker [13] was propagated on Swine
Testicle cells. Wild type HSV-1 strain F [14] and HSV-1 mutants
SDUS5-LacZ [15] and LbetaA [16] were propagated on Vero
cells.
Cultivation and inoculation of primary trigeminal
ganglion neuronal cultures in a two-chamber model
Porcine trigeminal ganglia were excised from 2 to 4 week old
piglets and dissociated by enzymatic digestion with 0.2%
collagenase A (Roche)[17]. The harvested cells were resuspended
in culture medium (MEM supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.1 mg/ml
kanamycin and 30 ng/ml nerve growth factor (Sigma)) and seeded
in the inner chamber of an in vitro two-chamber model. The two-
chamber model consists of a polystyrene cloning cylinder (Sigma)
that is fixed with silicon grease on a collagen coated cover glass
inserted in a 6 well plate [11]. The inside of the cylinder forms the
inner chamber, the outside forms the outer chamber. One day
after seeding, cultures are washed with RPMI (Gibco) to remove
non-adherent cells and from then on, culture medium is changed
three times a week. After two to three weeks of cultivation, when
clear axon growth can be observed in the outer chamber, two-
chamber models are ready for inoculation with virus. Inoculation
with all viruses used was done by adding 26107 PFU to the outer
chamber. For PRV, two hours after inoculation of the outer
chamber, medium containing PRV was removed and the outer
chamber was washed twice with culture medium. Afterwards, new
culture medium supplemented with polyclonal antibodies to PRV
and guinea pig complement (Sigma) was added to prevent
continuous infection pressure from the outer chamber to neurons
in the inner chamber. For HSV-1, the virus was removed at 48 h
after inoculation by washing and new culture medium supple-
mented with monoclonal antibodies to HSV-1 gD and guinea pig
complement was added.
Antibodies, cytokines and chemicals
Polyclonal porcine FITC-labeled anti-PRV antibodies [18]
were used to detect late PRV proteins gB, gD and gE [17].
Monoclonal mouse-anti-PRV gD antibody 13D12 was described
earlier [18]. Polyclonal rabbit-anti-PRV IE180 antibody was a
kind gift from E. Tabare´s (Universidad Autonoma de Madrid,
Spain). Monoclonal mouse-anti-HSV-1 gD (124/468) and –anti-
HSV-1 ICP4 (sc56986) were purchased from Santa Cruz
Biotechnology and the neuronal marker rabbit-anti-neurofilament
200 from Sigma. Texas red-labeled goat-anti-rabbit antibodies
and FITC-labeled goat-anti-mouse antibodies were from Invitro-
gen. Recombinant porcine IFNalpha and IFNgamma were
purchased from R&D and X-gal and forskolin were obtained
from Sigma.
Quantification of the percentage viral antigen or beta-
galactosidase positive infected neurons
The ratio between viral antigen positive or beta-galactosidase
positive neurons in the inner chamber to the number of axons in
the outer chamber after different treatments was determined by
calculating viral antigen positive neuronal cell bodies (immuno-
fluorescence) or beta-galactosidase positive neurons (X-gal) in the
inner chamber and immunofluorescently labeled axons in the
outer chamber. For each experiment, at least 25 neurons with
outgrowth to the outer chamber were examined. Data shown
represent means 6 s.e.m. of independent triplicate assays.
Immunofluorescence staining procedures
Two-chamber systems to be used for immunofluorescent
detection of viral antigen positive neurons were washed in PBS
and fixed in 100% methanol for 20 min at 220uC. In two-
chamber systems to be used for analysis of beta-galactosidase
positive neurons in the inner chamber, the outer chamber was
fixed in 4% paraformaldehyde in PBS for 10 min and subse-
quently permeabilized in 0.2% TritonX-100 in PBS for 2 min. All
antibodies were diluted in PBS, all to a dilution of 1:100. Cells
were incubated with each antibody for 1 h at 37uC and were
washed two times between all incubation steps and after the last
incubation step.
Detection of beta-galactosidase activity
Cells in the inner chamber of two-chamber systems were fixed
in 2% paraformaldehyde-0.2% glutaraldehyde in PBS for 15 min
at RT and subsequently incubated with staining buffer (0.01% Na-
deoxycholate, 0.02% NP40, 2 mM MgCl2, 4.5 mM potassium
ferricyanide, 4.5 mM potassium ferrocyanide in PBS) for 5 min at
RT, followed by incubation with X-gal buffer (staining buffer
supplemented with 1 mg/ml X-gal) for 4 h at 37uC. Afterwards,
the inner chamber was washed twice with PBS and immediately
analyzed by light microscopy.
RT-PCR
RNA from cells grown in the inner chamber of two-chamber
systems was isolated and purified using the Trizol Plus RNA
purification kit (Invitrogen) according to manufacturer’s instruc-
tions, followed by a DNaseI digestion to degrade any contam-
inating DNA. RNA was reverse transcribed using SuperScript III
RT enzyme (Invitrogen) according to manufacturer’s instructions.
OligodT primers were used for reverse transcription of actin, PRV
IE180, PRV gB, PRV LAT, HSV-1 ICP0, HSV-1 gB and HSV-1
gD RNA and a gene specific primer (GSP-LAT) that allows
amplification of the 2 kb LAT intron (Table 1) was used for
reverse transcription of HSV-1 LAT RNA. The cDNA was then
amplified by PCR using the AccuPrime Taq DNA polymerase
system (Invitrogen). The sequences of primers, annealing temper-
atures and predicted lengths of amplified fragments can be found
in Table 1. Amplified PCR fragments were analyzed by agarose
gel electrophoresis and staining with Ethidium Bromide. The
specificity of amplified fragments was verified by predicted sizes
and by sequencing fragments that were purified from the agarose
gel. Purified fragments were subjected to cycle sequencing with a
Big Dye Terminator Cycle Sequencing kit v1.1 (Applied
Biosystems) and cycle sequencing reaction products were purified
using ethanol precipitation and separated on an ABI Genetic
Analyzer 310 (Applied Biosystems). Obtained fragment sequences
were compared with the NCBI nucleotide collection (nr/nt)
database using MegaBlast.
Confocal microscopy
Samples were analyzed on a Leica TCS SP2 laser scanning
spectrum confocal system (Leica Microsystems GmbH) linked to a
Leica DM IRBE microscope. Images were taken using a 63x oil
IFN-Induced Herpes Quiescence
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objective (NA 1.40-0.60) at RT and using Leica confocal
acquisition software. Adjustments of brightness and contrast were
applied to the entire images and were done using Adobe
Photoshop (Adobe Systems Inc.).
Results
PRV and HSV-1 proceed to productive replication in
porcine TG neurons
Porcine TG neurons grown in two-chamber models were
infected with PRV or HSV-1 by addition of virus to the outer
chamber. For PRV, at 24hpi, the vast majority of neurons (98%)
that had axons growing in the outer chamber were positive for late
viral antigens (Fig. 1C), indicating that PRV proceeds to
productive infection in virtually all infected neurons. In some
infected neurons at 24hpi, late PRV protein expression was limited
to the neuronal cell body (Fig. 1A) while in others, infection had
already spread to non-neuronal cells surrounding the cell body
(Fig. 1B). Initiation of productive infection was less efficient when
TG neurons were infected with HSV-1, but still resulted in 12% of
the neurons with axonal outgrowth in the outer chamber being
positive for the late HSV-1 antigen gD at 48hpi (Fig. 1F). As for
PRV, some neurons showed HSV-1 gD expression limited to the
neuronal cell body (Fig. 1D) while in others infection had already
spread from the cell body to surrounding non-neuronal cells at this
time point (Fig. 1E). To ensure that the substantial difference in
percentage of productively infected neurons between HSV-1 and
PRV was not due to the difference in antibodies used (polyclonal
mixture for PRV versus monoclonal gD-specific for HSV-1),
experiments with PRV were repeated using a PRV gD-specific
monoclonal antibody. Again, the vast majority (75.366.2%) of
neurons with axonal outgrowth in the outer chamber were positive
at 24hpi with PRV. To analyze whether the limited percentage of
productively HSV-1 infected neurons is due to a hampered HSV-1
entry in porcine TG neurons, neurons were infected with the
SDUS5-LacZ HSV-1 mutant carrying the reporter gene LacZ
under control of the human CMV MIEP promoter inserted in the
non-essential US5 gene [15]. X-gal staining of infected cultures
showed that over 90% of neurons with axons growing into the
outer chamber were beta-galactosidase positive at 24hpi (Fig. 1F),
indicating that HSV-1 efficiently enters porcine TG neurons but
does not efficiently initiate productive replication. To evaluate
whether the block in productive HSV-1 replication occurs before
or after expression of the earliest viral proteins (immediate early or
IE proteins), HSV-1 experiments were repeated using an ICP4-
specific monoclonal antibody. This resulted in a percentage of
positive neurons (11.761.5%) similar to the percentage observed
using gD-specific antibodies, indicating that the neurons that do
not proceed to productive HSV-1 replication are halted before
detectable ICP4 protein expression. Overall, these results indicate
that upon viral entry, PRV efficiently proceeds to productive
replication. For HSV-1, 612% of infected neurons proceed to
productive replication whereas the others are halted at a stage very
early in infection.
Interferon alpha suppresses PRV and HSV-1 productive
replication in TG neurons for several days
The effect of IFNalpha on the expression of late viral proteins
upon inoculation with both viruses was analyzed. Two-chamber
systems were pretreated with IFNalpha for 24 h and after
infection, IFNalpha remained present in the inner chamber for
the entire experiment. A dose dependent decrease was observed in
the number of PRV infected neurons expressing late viral proteins
at 24hpi, ranging from 3661% late viral antigen positive neurons
with 0.5 U/ml IFNalpha (data not shown) to 261% with 500 U/
ml (Fig. 2A). The latter concentration was selected for all further
experiments. The suppressive effect of IFNalpha on PRV
replication was sustained over a longer period of time since at
5dpi, still only 1064% of infected neurons were late viral antigen
positive (Fig. 2A). For HSV-1, the suppressive effect of IFNalpha
was even more pronounced since not a single HSV-1 gD positive
Table 1. RT-PCR specifications.
primer sequence (59-39) annealing temp. predicted length
porcine actin forward: ATGCAGAAGGAGATCACGGC 50 199
reverse: AGTCCGCCTAGAAGCATTTG
PRV IE180 forward: ACGCGAGAGGAAGTAGGGAG 57 393
reverse: GTACCTGCACCGCAGTGAAG
gB forward: CCTCCTCGACGATGCAGTTG 59 281
reverse: CACGAACCGCTTCACAGACC
LAT forward: CATAAAGCCAGTTGAAGACGGGG 59 526
reverse: TAGAGGGTCTTGGGGATGTTGG
HSV-1 ICP0 forward: GCCCACTATCAGGTACAC 55 301
reverse: CACGGAACTGTTCGAGAC
gB forward: TGGCGTCGGAAGAGAATCGG 59 213
reverse: AGCAGGTCGACGGCTTCTAC
gD forward: AGCCAAGGGCTCCTGTAAG 58 352
reverse: GTCCTGGATCGACGGTATGTG
GSP-LAT TGGTGGACCAGACGGGAAAC
LAT forward: CCGCGATACATCCAACAC 53 383
reverse: GAACAGCCTCTGGATGAC
Primer sequences and annealing temperatures (uC) used in RT-PCR and predicted length (bp) of amplified fragments.
doi:10.1371/journal.pone.0013076.t001
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Figure 1. Productive replication of PRV and HSV-1 in porcine TG neurons. Confocal images of TG neuronal cultures in the inner chamber at
24hpi with PRV (A,B) and 48hpi with HSV-1 (D,E) stained for neurofilament (red) and late viral antigens (green) (bar = 50 mm). Percentage of neurons
with axons growing out to the outer chamber that show viral antigens at 24hpi with PRV (C) and 48hpi with wt HSV-1 (F, left bar) and beta-
galactosidase activity at 24hpi with SDUS5-LacZ HSV-1 (F, right bar). Data represent the mean 6 s.e.m. of three independent experiments.
doi:10.1371/journal.pone.0013076.g001
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infected neuron was detected, both at 2 and 5dpi (Fig. 2B). Both
for PRV and HSV-1, in the absence of IFNalpha, cytopathic effect
was complete well before 5dpi. These results indicate that
IFNalpha is able to efficiently suppress alphaherpesvirus replica-
tion in porcine TG neurons for several days.
Interferon alpha suppresses PRV IE180 and HSV-1 ICP4
protein expression in TG neurons
To determine whether IFNalpha not only suppresses late viral
protein expression, but may also affect IE protein expression, levels
of ICP4 of HSV-1 or the corresponding IE180 protein of PRV
were analyzed in IFNalpha–treated two-chamber systems. For
HSV-1, IFNalpha treatment resulted in fast and efficient
suppression of ICP4 protein levels, leading to undetectable ICP4
levels at both 2dpi and 5dpi. For PRV, IFNalpha-mediated
suppression of IE180 appeared to be less efficient and slower,
resulting in 91.5614.8% of IE180-positive neurons with axonal
outgrowth in the outer chamber at 1dpi, and 46.163.2% of
IE180-positive neurons at 5dpi. These results indicate that
IFNalpha is able to suppress alphaherpesvirus IE protein levels
in porcine TG neurons, and that this appears to occur more
efficiently in HSV-1-infected neurons compared to PRV-infected
neurons.
Interferon alpha induces a stably suppressed quiescent
PRV and HSV-1 infection
During virus latency, the virus is present in a stably suppressed
state. In other words, latency persists, even when the suppressive
agent is removed. To analyze whether IFNalpha is able to induce
such a stably suppressed state of alphaherpesvirus infection, we
analyzed whether or not withdrawal of IFNalpha at 5dpi resulted
in re-expression of late viral antigens in TG neurons. For PRV,
infection was stably suppressed in 60% of the neurons, as they did
not express detectable levels of late viral proteins at 3 days post
IFNalpha withdrawal (Fig. 2A). For HSV-1, none of the neurons
initiated expression of detectable levels of HSV-1 gD even at 7
Figure 2. IFNalpha induces a reactivatable, latent PRV and HSV-1 infection in porcine TG neurons. Percentage infected neurons that are
late viral antigen positive at 1, 5 and 8dpi with PRV (A) and at 2, 5 and 12dpi with HSV-1 (B) in the presence or absence of 500 U/ml IFNalpha. For the
neurons fixed at 8dpi with PRV and 12dpi with HSV-1, medium containing IFNalpha was washed out at 5dpi and replaced with new culture medium
or new culture medium supplemented with forskolin (200 mM). Data represent the mean 6 s.e.m. of three independent experiments.
doi:10.1371/journal.pone.0013076.g002
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days after withdrawal of IFNalpha (12dpi) (Fig. 2B), showing that
all HSV-1 infected TG neurons were in a stably suppressed
quiescent state of infection.
Forskolin treatment triggers PRV and HSV-1 reactivation
in neurons containing quiescent virus
Alphaherpesvirus latency is defined as a functional viral genome
retained in neurons in the absence of virus particles but capable to
reactivate resulting in production of new infectious virus [4].
Forskolin is a known stimulus of alphaherpesvirus reactivation
[19–21]. Therefore, we analyzed whether forskolin was able to
reactivate PRV and HSV-1 in the neurons containing stably
suppressed virus. Again, IFNalpha was withdrawn at 5dpi and
medium supplemented with forskolin (200 mM) was added. For
PRV, 70% of the infected neurons were late viral antigen positive
at 3 days post IFNalpha withdrawal (Fig. 2A), often with virus
spread to neighbouring non-neuronal cells, indicating that
forskolin treatment induced reactivation of PRV in 50% of
neurons that contained stably suppressed virus at 5dpi. For HSV-
1, a similar experiment was performed but medium supplemented
with forskolin was added twice, at 5dpi (when IFNalpha was
withdrawn) and again at 8dpi. Analysis of neurons at 12dpi
showed that forskolin had induced reactivation of HSV-1 since
11% of infected neurons were positive for HSV-1 gD at that time
point (compared to 0% without forskolin) (Fig. 2B), often with
spread of the virus to neighbouring non-neuronal cells. Reactiva-
tion ultimately led to complete cytopathic effect in the inner
chamber (data not shown). Forskolin triggers reactivation but was
found not to prevent the IFNalpha–mediated suppression of
productive viral replication, since addition of IFNalpha and
forskolin in parallel did not influence the ability of IFNalpha to
suppress productive viral replication (data not shown). Overall,
these data show that forskolin can reactivate HSV-1 and PRV
from IFNalpha–induced quiescence.
PRV and HSV-1 express LATs during in vitro latency-like
quiescence
During HSV-1 and PRV latency in vivo, expression of LATs is
frequently observed [22,23]. To determine LAT expression during
in vitro latency-like quiescence by wild type HSV-1 and PRV, RT-
PCR was performed on RNA isolated from TG neurons derived
from these two-chamber models that were i) mock infected, ii)
productively infected, and iii) uniformly quiescently infected
(Fig. 3A,B). For PRV, all three quiescently infected cultures
(CPE negative at 5dpi) examined were negative for immediate
early (IE180) and late (gB) viral RNA but one was positive for LAT
RNA (Fig. 3A). For HSV-1, all three quiescently infected cultures
examined were negative for late (gB and gD) viral RNA but 2 were
positive for LATs (Fig. 3B). RT-PCR assays contained quite
prominent aspecific amplification signals, which are likely due to
the high number of PCR cycles needed to detect sufficient signal.
Specificity of the bands was confirmed via sequencing and
Figure 3. PRV and HSV-1 express LATs during in vitro latency. (A,B) RT-PCR analysis of actin and viral immediate early (IE180 and ICP0), late
(gB and gD) and LAT transcript RNA isolated from neuronal cultures that were either mock infected, productively infected with PRV (A, 1dpi) or HSV-1
(B, 2dpi), or latently infected with PRV (A, 5dpi with IFNalpha) or HSV-1 (B, 9dpi, 4 days post IFNalpha withdrawal). For each condition three different
samples were analyzed and representative gels are shown. For HSV-1, two samples of 9dpi, 4 days post IFNalpha withdrawal are shown, one without
and one with detectable ICP0 transcript expression. Specific bands are marked with a black arrowhead. (C) Percentage of infected neurons positive
for LAT promoter-driven beta-galactosidase at 2 and 5dpi with HSV-1 LbetaA in the presence or absence of 500 U/ml IFNalpha. Data represent the
mean6 s.e.m. of three independent experiments. (D) Light microscopic images of uniform (i,ii) and focal (iii) LAT promoter-driven beta-galactosidase
distribution during the acute stage (2dpi without IFNalpha, i, ii) or the latent stage (5dpi with IFNalpha, iii) of infection with HSV-1 LbetaA. Arrows
point to infected non-neuronal cells (i), dashed line marks contour of neuronal cell body in (iii) (bar = 20 mm).
doi:10.1371/journal.pone.0013076.g003
IFN-Induced Herpes Quiescence
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e13076
contamination by viral genomic DNA was excluded by DNAseI
treatment and by performing control reactions in the absence of
reverse transcriptase. The RT-PCR assays show that both PRV
and HSV-1 express detectable levels of LATs in a subset of
infected porcine TG neurons during IFNalpha induced latency-
like quiescence. Interestingly, one of the three quiescently HSV-1
infected cultures examined, which were all negative for gD RNA,
was positive for ICP0 transcripts (Fig. 3B).
The HSV-1 LAT promoter is activated over time during
latency-like in vitro quiescence
For HSV-1, LAT promoter activity was assessed during
IFNalpha induced latency-like quiescence in vitro. Two-chamber
systems were infected with the LbetaA HSV-1 mutant carrying a
LacZ reporter gene under control of the LAT promoter [16] in the
presence or absence of IFNalpha. X-gal staining of cultures not
treated with IFNalpha showed that 16% of infected neurons were
beta-galactosidase positive at 48hpi (Fig. 3C). This percentage is
similar to the percentage of HSV-1 gD positive neurons after wild
type HSV-1 infection at 48hpi (12%). In the presence of IFNalpha,
we observed an increase of beta-galactosidase positive infected
neurons over time to about 50% positive neurons at 5dpi (Fig. 3C).
As a control, no evidence for beta-galactosidase activity was found
at 5dpi in the presence of IFNalpha in neurons infected with the
SDUS5-LacZ HSV-1 mutant carrying the reporter gene LacZ
under control of the human CMV MIEP promoter. The
activation of the LAT promoter over time suggests a gradual de-
repression of the LAT promoter. Analysis of beta-galactosidase
distribution in 620 neurons in either lytically infected neurons
(2dpi in the absence of IFNalpha) or quiescently infected neurons
(5dpi in the presence of IFNalpha) indicated that in lytically
infected neurons, beta-galactosidase distribution was generally
uniform throughout the neuronal cell body (Fig. 3Di, ii) and
sometimes associated with spread of infection to surrounding non-
neuronal cells (Fig. 3Di), while a more focal beta-galactosidase
distribution was frequently found in quiescently infected neurons
(Fig. 3Diii). In summary, in the presence of IFNalpha, HSV-1
LAT promotor activity can be observed in up to650% of infected
neurons at 5dpi. Since this percentage is higher than the
percentage of neurons that proceed to a productive replication
in the absence of interferon (12%, Fig. 1F), this suggests that at
least a fraction of the neurons that do not show the capacity to
proceed to productive replication in the absence of IFNalpha do
show LAT promoter activity during prolonged incubation with
IFNalpha.
Discussion
In the current report, we show that addition of IFNalpha to
two-chamber systems of porcine TG neurons is sufficient to induce
a quiescent PRV and HSV-1 infection that shows strong
similarities to in vivo latency.
Besides the insights in alphaherpevirus latency/reactivation
generated by in vivo studies in animals, ex vivo explants of latently
infected neurons, and from biopsies of deceased individuals, over
the years, several very valuable in vitro models have been
developed that have increased our understanding of HSV
quiescence and latency. Some of the most notable of these in
vitro systems are based on the use of antiviral drugs, mainly
nucleoside analogues that act as viral DNA chain terminators.
Such drugs have been shown to induce a stably suppressed state of
HSV infection that shows similarities to in vivo latency. Cells used
in these models vary from fibroblasts over neuronal cell lines (e.g.
PC12) to primary rat dorsal root ganglion neurons [24–28]. Like
noncytotoxic lytic granules and type II interferon, antiviral drugs
like acyclovir have also been shown to have the capacity to prevent
HSV reactivation in vitro upon explantation of TG neurons
obtained from latently infected mice [29–31]. Some of the other in
vitro models of HSV latency are based on the use of replication-
defective, attenuated virus strains [32]. Still other models are based
on a reversible, temperature-dependent suppression of virus
replication [33,34]. Some previous in vitro latency models
contained IFN – however, simultaneous addition of nucleoside
analogues was required to establish quiescence [25–27]. Since
addition of nucleoside analogues without IFN also prevents viral
replication and leads to quiescence [28], these data were
inconclusive on a potential involvement of IFN in latency
establishment. In our current model, addition of IFNalpha is
sufficient to establish latency-like quiescence, without the need for
nucleoside analogues. This important difference is perhaps due to
the use of a two-chamber system that allows an in vivo-like route of
infection of neurons, via retrograde axonal spread. It has been
suggested before that the long distance retrograde transport of
HSV in neurons results in reduced levels of the viral VP16
transactivator reaching the nucleus [35]. Without a two-chamber
system, virus can access the neurons via the cell body, thereby
circumventing retrograde axonal spread.
The obtained results indicate a strong similarity between the
currently described in vitro quiescence and alphaherpesvirus
latency in vivo. First of all, our results show that both PRV and
HSV-1 express detectable levels of LATs in a subset of quiescently
infected in vitro systems. It will be interesting to further explore
LAT expression in the in vitro latency model, e.g. by determining
nuclear localization of the LAT transcripts. Our observation that
not all cultures contain detectable LAT expression appears to be in
line with the notion that in vivo a varying number of latently HSV-
1 infected human TG neurons expresses detectable levels of LATs
[36]. We observed that some quiescently infected cultures are
positive for both LAT and ICP0 transcripts. Although we cannot
formally rule out the possibility that these LAT/ICP0 mRNA
double-positive quiescent cultures may consist of neurons that
express either LAT or ICP0 mRNA, it is also possible that
quiescently infected neurons express both transcripts at the same
time. Interestingly, there is increasing evidence for the presence of
ICP0 transcripts in ganglia of humans and mice latently infected
with HSV-1 [37–39], and our current data may therefore be in
line with indications that ICP0 protein expression in latently
infected neurons may at least partly be blocked at the post-
transcriptional level, probably due to microRNA activity of LATs
and perhaps other, unknown, viral and host factors [37,39–41].
Using a previously described HSV-1 recombinant expressing beta-
galactosidase under control of the LAT promoter [16], a focal
beta-galactosidase distribution was observed in latently infected
neurons. Such a focal beta-galactosidase distribution was also
observed during in vivo latency in ganglia of mice latently infected
with the LbetaA mutant and with another HSV mutant expressing
LacZ under control of the LAT promoter [16,42]. It has been
suggested that the focal beta-galactosidase distribution may be due
to physiological differences between lytically and latently infected
neurons.
Our results indicate that IFNalpha leads to efficient establish-
ment of PRV and HSV-1 latency-like quiescence in TG neurons in
vitro. Based on these data, it is tempting to speculate that IFNalpha
also represents a key immune component involved in the efficient
establishment of alphaherpesvirus latency in sensory neurons in
vivo. Some in vivo data may support this hypothesis: several reports
indicate that impaired IFN responses in vivo can result in
uncontrolled lytic virus replication and, often fatal, afflictions of
IFN-Induced Herpes Quiescence
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the central nervous system, including herpes simplex encephalitis
in humans [43,44], and increased replication efficiency of strongly
attenuated HSV-1 mutants in TG neurons of mice [45]. Based on
the current in vitro data, it will be interesting to further investigate
if type I IFNs indeed act as a double-edged sword in vivo: on the
one hand protecting the host from severe infection by alphaher-
pesviruses, on the other hand contributing to their lifelong
persistence in a latent form.
In vivo, there is evidence that type II IFN (IFNgamma), mainly
produced by CD8+ T lymphocytes, plays only a minor additional
role to type I IFNs in controlling early acute infection [45,46] but
is important to prevent reactivation of alphaherpesviruses from
latency [31,47]. Further in line with the similarity between
alphaherpesvirus in vivo latency-like quiescence and the currently
described in vitro model, we found that IFNgamma, although
unable to suppress PRV replication over longer periods of time
and therefore unable to induce PRV quiescence in vitro as observed
for IFNalpha, is able to maintain PRV quiescence in vitro (data not
shown). Although speculative at this point, together with the
literature data, this may suggest that especially type I IFNs, as a
crucial factor of the innate antiviral immunity, may be of
importance during establishment of latency whereas type II IFN
produced by the adaptive immunity are of crucial importance in
maintaining the virus in a latent state and preventing reactivation.
It will be interesting to determine whether the latency-like
quiescent state of infection is the result of IFNalpha directly
promoting the establishment of latency/quiescence, or, alterna-
tively, of an IFNalpha-mediated inhibition of lytic replication that
indirectly promotes latency/quiescence. Dissecting which IFNal-
pha-induced effectors are involved in the induction of quiescence
will aid to clarify this. Both in PRV and HSV, IFNalpha
suppressed protein expression levels of IE genes ICP4/IE180,
suggesting that IFNalpha–mediated IE suppression may be a key
element in the ability of this innate immune effector to establish
quiescence. In line with this hypothesis, we observed that the
percentage of neurons that still show detectable IE180 protein
levels at 5dpi with PRV in the presence of IFNalpha correlates
well with the percentage of neurons that are not in a stable
quiescent infection at that time point and proceed to productive
replication upon IFNalpha withdrawal (46% versus 40%).
In summary, this study presents a novel and unique in vitro
system to dissect aspects of the latency/reactivation cycle of wild
type alphaherpesviruses and points to IFNalpha as a potential
driving force in efficient alphaherpesvirus latency establishement.
In addition, the currently described in vitro model may provide a
unique tool to screen possible drug candidates that interfere with
the latency/reactivation cycle.
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